docetaxel
Showing 1 - 25 of 1,347
Advanced NSCLC Trial (Trilaciclib+Envafolimab+Docetaxel, Envafolimab+Docetaxel, Docetaxel)
Not yet recruiting
- Advanced Non-Small Cell Lung Cancer
- (no location specified)
Jun 16, 2023
Serplulimab,Gastric Cancer, Adjuvant Therapy Trial in Shanghai (Serplulimab, Docetaxel, S1)
Recruiting
- Serplulimab,Gastric Cancer, Adjuvant Therapy
- Serplulimab
- +2 more
-
Shanghai, ChinaZhang Zizhen
Mar 3, 2023
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,
Not yet recruiting
- Androgen-Independent Prostatic Cancer
- +8 more
- lorigerlimab
- +2 more
- (no location specified)
May 4, 2023
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial (Standard ADT (androgen deprivation therapy), Standard Darolutamide,
Not yet recruiting
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Standard ADT (androgen deprivation therapy)
- +2 more
- (no location specified)
Jan 6, 2023
Metastatic Prostatic Adenocarcinoma Trial in Charleston (Docetaxel, Degarelix)
Active, not recruiting
- Metastatic Prostatic Adenocarcinoma
- Docetaxel
- Degarelix
-
Charleston, South CarolinaMedical University of South Carolina
Jan 30, 2023
NSCLC Trial (SGN-B6A, docetaxel)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- SGN-B6A
- docetaxel
- (no location specified)
Aug 21, 2023
Breast Cancer Trial in Beijing (QL1701, Herceptin®, Docetaxel)
Active, not recruiting
- Breast Cancer
- QL1701
- +2 more
-
Beijing, ChinaCancer Hospital,Chinese Academy of Medical Sciences
Nov 18, 2022
Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemo Effect Trial in Nanjing (Docetaxel, Rezvilutamide)
Recruiting
- Metastatic Prostate Cancer
- +2 more
- Docetaxel
- Rezvilutamide
-
Nanjing, Jiangsu, ChinaUrology dpt, First Affiliated Hospital of Nanjing Medical Univer
Aug 2, 2023
NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)
Not yet recruiting
- Non-small Cell Lung Cancer
- Savolitinib
- Docetaxel
-
Guangzhou, Guangdong, ChinaDepartment of Thoracic Surgery and Oncology, The First Affiliate
Mar 17, 2023
Hyperthermic Intraperitoneal Chemo Trial in Guangzhou (Docetaxel)
Recruiting
- Hyperthermic Intraperitoneal Chemotherapy
- Docetaxel
-
Guangzhou, Other (Non U.s.), ChinaSun Yat-sen Memorial Hospital
Jun 6, 2022
Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)
Not yet recruiting
- Head Neck
- Squamous Cell Carcinoma of Head and Neck
- Pembrolizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Sep 14, 2023
Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)
Recruiting
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Docetaxel
- +3 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023
Soft Tissue Sarcoma Trial in Winston-Salem (drug, radiation, procedure, other)
Recruiting
- Soft Tissue Sarcoma
- Gemcitabine
- +4 more
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Jan 26, 2023
Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)
Not yet recruiting
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- HMBD-001
- +2 more
-
Sydney, New South Wales, AustraliaGenesisCare North Shore
Jun 20, 2023
Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)
Completed
- Breast Neoplasms
- Epirubicin
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Oct 26, 2022
Prostate Cancer, Castration-resistant Prostate Cancer Trial in São Paulo (Docetaxel, Enzalutamide)
Active, not recruiting
- Prostate Cancer
- Castration-resistant Prostate Cancer
- Docetaxel
- Enzalutamide
-
São Paulo, SP, BrazilInstituto do Câncer do Estado de São Paulo
Sep 14, 2022
NSCLC Trial (Pembrolizumab, Docetaxel)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Pembrolizumab
- Docetaxel
- (no location specified)
Aug 18, 2022
Hormone Sensitive Metastatic Prostate Cancer, DNA Damage Repair Deficiency, Chemo Effect Trial in Nanjing (Docetaxel,
Recruiting
- Hormone Sensitive Metastatic Prostate Cancer
- +3 more
- Docetaxel
- +2 more
-
Nanjing, Jiangsu, ChinaDepartment of Urology, Drum Tower Hospital, Medical School of Na
Jul 13, 2022
Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)
Not yet recruiting
- Non-small Cell Lung Adenocarcinoma
- Squamous Cell Carcinoma of Lung
- SI-B001
- Docetaxel
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jul 5, 2023
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head
Recruiting
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- +4 more
- Duvelisib
- Docetaxel
-
Boston, MassachusettsDana Farber Cancer Institute
Jan 19, 2023
Breast Tumors, Locally Advanced or Metastatic Breast Cancer Trial in Guangzhou (utidelone, docetaxel)
Not yet recruiting
- Breast Neoplasms
- Locally Advanced or Metastatic Breast Cancer
- utidelone
- docetaxel
-
Guangzhou, Gangdong, ChinaShusen Wang
Jun 21, 2022
Non Small Cell Lung Cancer Trial in Davis, Orlando, Columbus (ONC-392, Docetaxel)
Not yet recruiting
- Non Small Cell Lung Cancer
- ONC-392
- Docetaxel
-
Davis, California
- +2 more
Jan 5, 2023
Breast Cancer Trial in Hangzhou (Docetaxel, Carboplatin, Trastuzumab)
Recruiting
- Breast Cancer
- Docetaxel
- +6 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 28, 2022